The risk of relapse is low in patients with advanced melanoma who have achieved complete remission (CR) on PD-1 inhibitors and discontinue treatment, research shows. An international study of 185 patients including Australians who discontinued treatment with either pembrolizumab or nivolumab – without indications such as disease progression or treatment-limiting toxicity – found overall 78% ...
Defining the optimal duration of anti-PD-1 therapy in melanoma
By Mardi Chapman
11 Feb 2020